With $75.1 million in cash and minimal competition, aTyr Pharma is well-positioned financially, making it a compelling ...

Xentria, a clinical-stage biopharmaceutical company advancing therapies for rare and serious diseases, today announced the successful completion of enrollment in the therapeutic dose-ranging phase of ...

Tulisa sported a dramatic swipe of makeup in a stunning Instagram snap on Wednesday after performing at The Gaydio Awards in ...

Clinical-stage biotech company aTyr Pharma (ATYR) has seen a significant 24% increase in stock value over the past week, as the company posted ...

Announced the fourth positive data and safety monitoring board (DSMB) review for the Phase 3 EFZO-FIT™ study. The independent ...

Q4 2024 Earnings Call Transcript March 13, 2025 aTyr Pharma, Inc. beats earnings expectations. Reported EPS is $-0.18, expectations were $-0.23. Operator: Good afternoon, ladies and gentlemen, and ...

Tyr Pharma Inc (ATYR) reports robust financial health and significant progress in its pivotal phase three study for pulmonary ...

Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT study reinforces ...

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the ...

Liz Kendall will set out how the government intends to reform the health benefits system on Tuesday afternoon, in a move ...

Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized by the formation of noncaseating granulomas, multisystem involvement, intrathoracic (pulmonary and lymph node ...